Sort
64,565 grants matching “drug discovery”
GalNAc-specific measurement of Galactose-deficient IgA1 as a Biomarker for IgA nephropathy
$977,756Tomasz Szul · Reliant Glycosciences Llc · R44 · FY2024 · DK
Antimicrobial Oligomers for BioDefense and Emerging Food Borne Infectious Disease
$977,658Gregory N. Tew · University Of Massachusetts Amherst · U01 · FY2009 · AI
Next-generation 5-nitroimidazoles against giardiasis
$977,645Lars Eckmann · University Of California, San Diego · U01 · FY2008 · AI
UC BRAID Center for Accelerated Innovation
$977,504Michael J Palazzolo · University Of California Los Angeles · U54 · FY2014 · HL
Preclinical development of Novo29, a new antibiotic
$977,463Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2021 · AI
Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral
$977,449Gai Liu · Microbiotix, Inc · R42 · FY2025 · AI
Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders
$977,355Shoko Iwai · Second Genome, Inc. · R44 · FY2019 · DA
Exploration, conservation, & development of marine biodiversity in Fiji and the S
$977,212Mark E Hay · Georgia Institute Of Technology · U19 · FY2016 · TW
Neuroprotection in Stroke Drug Development
$977,098Ruben J. Boado · Armagen Technologies, Inc. · R44 · FY2008 · NS
Neuroprotection in Stroke Drug Development
$977,098Ruben J. Boado · Armagen Technologies, Inc. · R44 · FY2007 · NS
INNOVATIVE CELL-BASED URINALYSIS FOR PATIENT ADHERENCE
$976,979Rama P Ramanujam · Swaasth, Inc. · R44 · FY2009 · AT
INSECT HERBIVORY IS A MAJOR LIMITING FACTOR FOR MAIZE PRODUCTION. THE IDENTITY OF THE SIGNAL(S) THAT CONVEY INFORMATION FROM THE AREA OF A PLANT INFESTED WITH INSECTS TO UNINFESTED SYSTEMIC TISSUE OR TO NEIGHBORING PLANTS, WHICH PREPARES THE UNCHALLENGED TISSUES FOR DEFENSE, REMAINS ELUSIVE. UNLIKE IN DICOTS WHERE SYSTEMIC SIGNALING IS BETTER UNDERSTOOD, MONOCOTS ARE MOST VULNERABLE TO INSECT DAMAGE AT THE SEEDLING STAGE WHERE ALL THE ABOVEGROUND ORGANS ARE CONNECTED TO EACH OTHER SOLELY THROUGH THEIR ROOT SYSTEMS. THIS REALIZATION PROMPTS THE HYPOTHESIS THAT IN INTRA-PLANT SIGNALING, IN ADDITION TO VOLATILE-MEDIATED PRIMING, A DAMAGED LEAF-DERIVED NON-VOLATILE SIGNAL MUST TRAVERSE ROOTS BEFORE ACCESSING OTHER LEAVES. TO TEST THIS HYPOTHESIS, THIS PROJECT WILL UTILIZE A UNIQUE COLLECTION OF MAIZE KNOCK-OUT MUTANTS AFFECTED IN SYSTEMIC SIGNALING, COUPLED WITH THE POWER OF TRANSCRIPTOME AND OXYLIPIN PROFILING TO IDENTIFY (1) A NON-VOLATILE SIGNAL(S) PRODUCED IN AN INSECT DAMAGED AREA, WHICH IS SUBSEQUENTLY TRANSPORTED VIA PHLOEM INTO ROOTS BEFORE SYSTEMIC DISTRIBUTION; AND/OR (2) A SECONDARY SIGNAL(S) PRODUCED IN ROOTS TRANSPORTED BY XYLEM TO THE REST OF THE PLANT. THE OTHER MAJOR GOAL OF THE PROJECT WILL EXPLORE A VOLATILE ORIGIN OF INSECT-INDUCED LONG DISTANCE INTER- AND INTRA-PLANT SIGNALING. THIS PROPOSAL'S CENTRAL PREMISE IS ROOTED IN THE DISCOVERY THAT MAIZE GREEN LEAF VOLATILES (GLV)- AND TRAUMATIN (TA)-DEFICIENT LIPOXYGENASE10 (LOX10) MUTANT IS UNABLE TO SYSTEMICALLY INDUCE NOT ONLY THE MAJOR DEFENSE HORMONES ABA AND JA, BUT ALSO A NUMBER OF NOVEL OXYLIPINS NAMED HERE AS SYSTEMIC OXYLIPIN SIGNALS (SOS) IN RESPONSE TO LOCAL HERBIVORY. THIS AND MASSIVE TRANSCRIPTOME REPROGRAMMING OBSERVED IN WILD TYPE BUT NOT IN THE LOX10 MUTANT ROOTS SUGGEST THAT LOX10 IS A MASTER REGULATOR OF HERBIVORE-INDUCED SYSTEMIC RESISTANCE (ISR). LOX10 MUTANTS AND OTHER SOS MUTANTS IMPACTED IN LONG-DISTANCE SIGNALING, WILL BE USED AS EXCELLENT GENETIC TOOLS TO ELUCIDATE THE ISR SIGNALS. THE PROJECT IS EXPECTED TO YIELD: 1) NOVEL VOLATILE AND NON-VOLATILE SOS, SIGNALING PEPTIDES, AND ISR GENETIC NETWORKS. 2) IDENTIFICATION OF NEW FUNCTIONS FOR UNCHARACTERIZED OXYLIPINS; 3) CONNECT THE BELOW-GROUND ORGANS WITH THE PRODUCTION AND TRANSDUCTION OF ORGANISMAL-WIDE SYSTEMIC AND INTER-PLANT DEFENSE SIGNALING. THIS PROJECT IS INSPIRED BY THE JUXTAPOSITION BETWEEN PLANT VS HUMAN OXYLIPIN BIOLOGY KNOWLEDGE. HUMAN OXYLIPIN RESEARCH HAS REVOLUTIONIZED DIVERSE MEDICAL FIELDS RESULTING IN THE DEVELOPMENT OF ~60% OF THE CURRENT HUMAN DRUGS, ALL OF WHICH TARGET OXYLIPIN PRODUCTION, TRANSPORT, PERCEPTION, OR EFFECTS. WITH THE EXCEPTION OF THE PROGRESS MADE IN OUR UNDERSTANDING OF THE DEFENSE HORMONE JA, PRACTICALLY NOTHING IS KNOWN ABOUT THE BIOLOGICAL RELEVANCE OF THE OTHER ~600 REPORTED PLANT OXYLIPIN SPECIES. BRIDGING THE GAPS IN KNOWLEDGE AND UNCOVERING THE BIOLOGY OF PLANT OXYLIPINS IN THE INDUCTION OF LONG LASTING SSYTEMIC RESISTANCE IS THE MAJOR FOCUS OF THIS PROJECT.
$976,812Texas A&M Agrilife Research · · FY2017 · National Institute of Food and Agriculture
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy
$976,740David Richard Light · Illexcor Therapeutics, Llc · R44 · FY2023 · HL
Bay Area Cancer Target Discovery and Development
$976,551Michael T McManus · University Of California, San Francisco · U01 · FY2023 · CA
Efficient patient-specific cell generation by image-guidance
$976,531Shih-Jong J Lee · Drvision Technologies, Llc · R44 · FY2014 · HL
Identifying chemical probes against all essential genes
$976,497Ronald Wayne Davis · Stanford University · R01 · FY2006 · HG
DCTD Human Toxicology and Pharmacology
$976,485David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2017 · CA
Targeting a Novel Regulator of Brain Aging and Alzheimer's Disease
$976,136Bruce A Yankner · Harvard Medical School · R01 · FY2016 · AG
Novel Probes for the Monoamine Transporters
$976,135Amy Hauck Newman · National Institute On Drug Abuse · ZIA · FY2025 · DA
Novel Dopamine D3/D2 Receptor Ligands
$976,135Amy Hauck Newman · National Institute On Drug Abuse · ZIA · FY2025 · DA
Developing small molecule therapeutics for Ebola hemorrhagic fever virus
$976,031Arnab Basu · Microbiotix, Inc · R01 · FY2010 · AI
Unraveling Cytotoxic and Thrombotic Signals in COVID-19
$975,922Yogendra Kanthi · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL
Human Translational Studies of Vascular Thrombosis and Inflammation
$975,922Yogendra Kanthi · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
$975,880Ac Matin · Stanford University · UH3 · FY2017 · TR
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
$975,880Ac Matin · Stanford University · UH3 · FY2016 · TR